Notícias e Atividades da Neurona Therapeutics

Fusão, aquisição e financiamento envolvendo Neurona Therapeutics.

• UCB has announced the acquisition of Neurona Therapeutics  (publicado em 20 de abril de 2026).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Neurona Therapeutics

• Cory Nicholas, Co-Founder, Chief Executive Officer and Director
• Ray Kelleher, Director
• Tim Kutzkey, Chairman of the Board

Recentes movimentos de executivos em Neurona Therapeutics

• Eduardo Dunayevich, ingressou na Companhia como Chief Medical Officer  (Notícia publicada em 19 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Neurona Therapeutics.

Neurona Therapeutics possui 2.406 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (publicado em 4 de junho de 2026).
• Oak Hill Bio acaba de anunciar uma arrecadação de fundos de 33 milhões de dólares. (publicado em 4 de junho de 2026).
• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Patrick Enright - Director da CuraSen Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Neurona Therapeutics

• Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX 1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting
• Neurona Therapeutics Presents New Long-Term Clinical Data from NRTX-1001 Cell Therapy Trials at 2025 Annual Meeting of the American Epilepsy Society
• Neurona Therapeutics Appoints Dr. Eduardo Dunayevich as Chief Medical Officer
• Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
• Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)
• Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
• UChicago Medicine doctors provide pioneering stem cell surgery to patient with drug-resistant epilepsy | Newswise
• PressReader.com - Digital Newspaper & Magazine Subscriptions
• Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
• Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting
• View more press releases Close

Redes sociais sobre Neurona Therapeutics

• Neurona Therapeutics na Wikipedia, Google News e Yahoo Finance
• Neurona Therapeutics na LinkedIn, X (Twitter) e YouTube